We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy.
- Authors
Kwang Hyun Chung; Ji Kon Ryu; Jun Hyuk Son; Jae Woo Lee; Dong Kee Jang; Sang Hyub Lee; Yong-Tae Kim
- Abstract
Background/Aims: Second-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma (PDAC) that progresses following gemcitabine-based treatment has not been established. This study aimed to investigate the efficacy and safety of second-line combination chemotherapy with capecitabine and oxaliplatin (XELOX) in these patients. Methods: Between August 2011 and May 2014, all patients who received at least one cycle of XELOX (capecitabine, 1,000 mg/m2 twice daily for 14 days; oxaliplatin, 130 mg/m2 on day 1 of a 3-week cycle) combination chemotherapy for unresectable or recurrent PDAC were retrospectively recruited. The response was evaluated every 9 weeks, and the tumor response rate, progression-free survival and overall survival, and adverse events were assessed. Results: Sixty-two patients were included; seven patients (11.3%) had a partial tumor response, and 20 patients (32.3%) had stable disease. The median progression-free and overall survival were 88 days (range, 35.1 to 140.9 days) and 158 days (range, 118.1 to 197.9 days), respectively. Patients who remained stable longer with frontline therapy (≥120 days) exhibited significantly longer progression-free and overall survival. The most common grade 3 to 4 adverse events in patients were vomiting (8.1%) and anorexia (6.5%). There was one treatmentrelated mortality caused by severe neutropenia and typhlitis. Conclusions: Second-line XELOX combination chemotherapy demonstrated an acceptable response and survival rate in patients with advanced PDAC who had failed gemcitabine-based chemotherapy.
- Subjects
PANCREATIC cancer diagnosis; CANCER patients; PANCREATIC cancer; RISK factors of pancreatic cancer; PANCREATIC cancer treatment; CANCER chemotherapy; OXALIPLATIN
- Publication
Gut & Liver, 2017, Vol 11, Issue 2, p298
- ISSN
1976-2283
- Publication type
Article
- DOI
10.5009/gnl16307